# Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout

> **NCT02139046** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 1790 (actual)

## Conditions studied

- Gout

## Interventions

- **DRUG:** Febuxostat IR
- **DRUG:** Febuxostat XR
- **DRUG:** Febuxostat placebo
- **DRUG:** Colchicine
- **DRUG:** Naproxen
- **DRUG:** Lansoprazole

## Key facts

- **NCT ID:** NCT02139046
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 1790 (ACTUAL)
- **Last updated:** 2016-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02139046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02139046, "Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02139046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*